Jingjing Li
- Oncology top 5%
- CAR-T cell therapy research 37
- Cancer Immunotherapy and Biomarkers 19
- Cutaneous Melanoma Detection and Management 5
- Pancreatic and Hepatic Oncology Research 4
- Immunology top 10%
- Immunotherapy and Immune Responses 10
- Oral Surgery top 5%
-
- Viral Infectious Diseases and Gene Expression in Insects 7
- Melanoma and MAPK Pathways 5
- CRISPR and Genetic Engineering 4
- Cited by
- OncologyImmunologyOral Surgery
- Partner nations
- ChinaUnited StatesHong Kong
In The Last Decade
Jingjing Li
87 papers receiving 1.4k citations
Peers
Comparison fields: 5 of 118
- Oncology 891
- Immunology 369
- Oral Surgery 71
- Cancer Research 97
- Molecular Biology 421
Countries citing papers authored by Jingjing Li
This map shows the geographic impact of Jingjing Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jingjing Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jingjing Li more than expected).
Fields of papers citing papers by Jingjing Li
This network shows the impact of papers produced by Jingjing Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jingjing Li. The network helps show where Jingjing Li may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Jingjing Li, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2025 | 1 | |
| 3 | 2025 | 0 | |
| 4 | 2025 | 2 | |
| 5 | 2024 | 1 | |
| 6 | 2024 | 4 | |
| 7 | 2024 | 5 | |
| 8 | 2024 | 3 | |
| 9 | 2023 | 6 | |
| 10 | 2023 | 5 | |
| 11 | 2023 | 3 | |
| 12 | 2023 | 0 | |
| 13 | 2022 | 3 | |
| 14 | 2022 | 22 | |
| 15 | 2020 | 2 | |
| 16 | 2019 | 20 | |
| 17 | 2019 | 21 | |
| 18 | 2017 | 15 | |
| 19 | 2016 | 123 | |
| 20 | 2016 | 16 |
About Jingjing Li
Jingjing Li is a scholar working on Oncology, Immunology and Cancer Research, having authored 96 papers that have together received 1.4k indexed citations. Recurring topics across this work include CAR-T cell therapy research (37 papers), Cancer Immunotherapy and Biomarkers (19 papers), Immunotherapy and Immune Responses (10 papers), Viral Infectious Diseases and Gene Expression in Insects (7 papers), Melanoma and MAPK Pathways (5 papers), Cutaneous Melanoma Detection and Management (5 papers), Pancreatic and Hepatic Oncology Research (4 papers) and CRISPR and Genetic Engineering (4 papers). The work is most often cited by research in Oncology (891 citations), Immunology (369 citations) and Oral Surgery (71 citations). Jingjing Li has collaborated with scholars based in China, United States and Hong Kong. Frequent co-authors include Hom‐Lay Wang, Peihua Lu, Junfang Yang, Rihe Liu, Dandan Li, Xizhi Wen, Leaf Huang, Xian Zhang, Xiaoshi Zhang and Manisit Das. Their work appears in journals such as Nature Communications, Blood and ACS Nano.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.